Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 1999

View Archived Issues

Algos and Endo to merge

New mouse model may shed light on abnormal tau function in AD

MediGene and Epitome enter licensing agreement for genital warts ointment

Hughes team reports advances in anti-HIV drug development

Antiasthmatic compounds from Otsuka bind to adenosine A3 receptors

Novel cannabinoids with improved activity as immunomodulators, analgesics and antiglaucoma agents

Cell Based Delivery receives grant for protein delivery technology

ASH meeting news: early clinical data presented on novel anticoagulant from SmithKline Beecham

Tokyo-based research team designs new carborane-containing estrogen receptor modulators

Teijin's activated protein C concentrate described to ASH participants

Gene Logic and Fujisawa collaborate to identify gene expression profiles for diabetes therapeutics

UCL-1848 as a new tool: the most potent nonpeptide SK channel blocker reported to date

Pharmacological characterization of a novel hypocholesterolemic agent in development at Taisho

Cambridge NeuroScience and Allergan extend ophthalmic research collaboration

Hughes Institute presents new anticancer compounds at two recent congresses

Antifungal collaboration extended by Genome Therapeutics and Schering-Plough

Role of MAPK pathway in the anticancer activity of farnesyltransferase inhibitors

Oxford GlycoSciences enters diabetes proteomics collaboration with Merck & Co.

Novel immunosuppressive mechanism described for FR-167653

Abbott acquires U.S. marketing rights to cefdinir

Neurogen updates drug development programs

Herbal extract has novel immunomodulating properties, potential in autoimmune, allergic conditions

Highlights from ASTMH meeting: iron chelator with potential in drug-resistant malaria

Kainate GluR5 antagonist reduces pain response in nonhuman primate model

PS-15 as monotherapy comparable to trimethoprim/sulfamethoxazole in mice with PCP

AR-116102, a 5-HT2A receptor inverse agonist, may be the first in a new class of antipsychotics

Peripheral analgesic agent without central effects designed at Toray

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...